Table III.
Study characteristics: Effect of breviscapine on blood fat and fibrinogen in patients with DN.
| Cholesterol (mmol/l) | Triglyceride (mmol/l) | HDL | Fg (g/l) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First author, year | Stage of DN | n | Age (years) | History of DM (years) | Intervention (breviscapine) | Treatment duration | Baseline | After intervention | Baseline | After intervention | Baseline | After intervention | Baseline | After intervention | Refs. |
| Wang, 2009 | III | T: 20 | 68 (mean) | 8 (mean) | T: 50 mg i.v.drip. Qd-a,x | 2 weeks | 5.8±0.9 | 5.8±0.7 | 1.9±0.8 | 1.9±0.7 | N | N | N | N | (19) |
| C: 20 | 70 (mean) | 10 (mean) | C: -a,x | 5.9±0.8 | 5.9±0.8 | 1.9±0.7 | 1.9±0.7 | ||||||||
| Huang, 2011 | III | T: 18 | 64 (mean) | 8 (mean) | T: 50 mg i.v.drip. Qd-a,x | 4 weeks | 5.8±0.9 | 5.8±0.7 | 1.9±0.8 | 1.9±0.7 | N | N | N | N | (20) |
| C: 18 | 66 (mean) | 10 (mean) | C: -a,x | 5.9±0.8 | 5.9±0.8 | 1.9±0.7 | 1.9±0.7 | ||||||||
| Wu, 2009 | IV | T: 36 | 62±2 | 5.01±1.8 | T: 50 mg i.v.drip. Qd-a,x | 1 month | 6.36±0.33 | 4.21±0.42 | 3.85±0.26 | 2.21±0.39 | N | N | 5.48±0.35 | 4.01±0.38 | (22) |
| C: 34 | 61±3 | 5.32±2.45 | C: -a,x | 6.48±0.26 | 5.95±0.31 | 3.65±0.41 | 3.35±0.31 | 5.35±0.36 | 5.15±0.28 | ||||||
| Huang, 2004 | III | T: 34 | 66.5±8.4 | 4.8±2.5 | T: 60 mg i.v.drip. Qd-u,x | 3 weeks | 5.59±1.34 | 3.87±1.46 | 2.25±0.97 | 1.56±0.78 | N | N | N | N | (23) |
| C: 28 | 65.3±6.5 | 4.58±2.1 | C: -u,x | 5.79±1.56 | 3.99±1.65 | 2.19±0.89 | 1.67±0.67 | ||||||||
| Qiao, 2009 | 62.25±8.9 | N | (26) | ||||||||||||
| IV | T: 52 | T: 40 mg i.v.drip. Qd-a,w | 4 weeks | 4.95±0.90 | 4.41±0.52 | 1.70±0.80 | 1.60±0.56 | 0.93±0.17 | 1.24±0.35 | N | N | ||||
| C: 40 | C: -a,w | 4.80±0.89 | 4.76±0.81 | 1.76±0.62 | 1.78±0.61 | 0.96±0.15 | 0.98±0.18 | ||||||||
| Zhong, 2011 | 41–65 (mean 54) | 3–8 | (27) | ||||||||||||
| III | T: 30 | T: 30 mg i.v.drip. Qd-a,x | 3 weeks | N | N | 2.86±0.45 | 1.84±0.29 | N | N | 5.99±0.75 | 3.83±0.53 | ||||
| C: 29 | C: -a,x | 2.73±0.35 | 2.25±0.27 | 5.86±0.75 | 4.62±0.31 | ||||||||||
| Wang, 2011 | III | T: 18 | N | N | T: 40 mg i.v.drip. Qd-b,x | 20 days | N | N | 2.90±0.31 | 1.74±0.16 | 1.26±0.12 | 4.52±0.08 | N | N | (39) |
| C: 18 | C: -b,x | 2.91±0.29 | 2.71±0.21 | 1.25±0.14 | 2.41±0.06 | ||||||||||
| Qian, 2011 | 37.5±65.8 | 6.7 (mean) | (40) | ||||||||||||
| III | T: 30 | T: 60 mg i.v.drip. Qd-u,x | 2 weeks | N | N | 2.80±0.31 | 1.93±0.33 | 1.45±0.43 | 4.85±0.49 | N | N | ||||
| C: 30 | C: -u,x | 3.70±1.09 | 2.99±0.40 | 1.74±0.45 | 2.50±0.29 | ||||||||||
| Huang, 2006 | IV | T: 22 | 18–76 (mean 56.8) | N | T: 40 mg i.v.drip. Qd-b,x | 2 weeks | N | N | N | N | N | N | 5.30±1.73 | 2.84±1.64 | (49) |
| C: 22 | 20–74 (mean 55.4) | C: -b,x | 5.45±1.52 | 4.05±1.43 | |||||||||||
| Li, 2011 | III | T: 50 | 41–72 (mean 52.5) | 4–11 (mean 8.2) | T: 60 mg i.v.drip. Qd-u,w | 15 days | 5.24±0.98 | 5.13±0.94 | 2.18±0.89 | 1.94±0.92 | N | N | N | N | (43) |
| C: 50 | 40–72 (mean 51.8) | 4–10 (mean 7.8) | C: -u,w | 5.28±0.96 | 5.25±0.93 | 2.16±0.86 | 2.14±0.94 | ||||||||
| Liu, 2003 | III–IV | T: 24 | 46±6.6 | 6.5±4.4 | T: 100 mg i.v.drip. Qd-b,x | 1 month | 9.33±3.22 | 4.12±1.45 | 2.69±1.53 | 2.06±1.61 | N | N | 5.18±0.61 | 3.13±1.03 | (46) |
| C: 24 | 46.2±6.8 | 6.2±4.8 | C: -b,x | 9.29±3.19 | 5.38±1.36 | 2.78±1.69 | 2.14±1.55 | 5.24±1.67 | 5.35±1.06 | ||||||
| Guo, 2008 | 54.2 | 9.8 | (48) | ||||||||||||
| IV | T: 34 | T: 50 mg i.v.drip. Qd-a,x | 20 days | N | N | N | N | N | N | 5.40±0.95 | 4.00±0.44 | ||||
| C: 30 | C: -a,x | 5.20±1.65 | 5.10±0.85 | ||||||||||||
| Kang, 2003 | III | T: 48 | 61.5±14.6 | 18.7±12.8 | T: 100 mg i.v.drip. Qd-b,x | 2 weeks | 7.12±0.46 | 6.48±0.21 | 2.50±0.27 | 1.79±0.24 | 0.86±0.15 | 1.08±0.17 | 3.75±0.62 | 2.81±0.57 | (11) |
| C: 20 | 62.3±11.5 | 18.2±11.6 | C: -b,x | 7.08±0.42 | 6.98±0.40 | 2.51±0.26 | 2.47±0.28 | 0.89±0.13 | 0.90±0.12 | 3.64±0.82 | 3.71±0.48 | ||||
| Xu, 2008 | III–IV | T: 36 | 42–79 | N | T: 100 mg i.v.drip. Qd-b,x | 4 weeks | 5.20±0.76 | 3.05±0.72 | 2.69±1.53 | 1.36±1.61 | N | N | 5.18±0.61 | 3.13±1.03 | (29) |
| C: 40 | 41–76 | C: -b,x | 5.18±0.73 | 4.98±0.68 | 2.78±1.61 | 2.64±1.55 | 5.35±1.67 | 5.24±1.06 | |||||||
| Liu, 2007 | 66±5 | 10±4 | (31) | ||||||||||||
| III | T: 22 | T: 50 mg i.v.drip. Qd-a,x | 2 weeks | 5.79±0.88 | 5.85±0.74 | 1.94±0.83 | 1.90±0.72 | N | N | N | N | ||||
| C: 23 | C: -a,x | 5.91±0.81 | 5.86±0.81 | 1.90±0.66 | 1.89±0.69 | ||||||||||
| Jiang, 2010 | III | T: 42 | 54.12±8.56 | N | T: 40 mg i.v.drip. Qd-a,x | 4 weeks | N | N | N | N | N | N | 4.72±2.01 | 2.53±1.65 | (33) |
| C: 38 | 58.15±7.25 | C: -a,x | 4.69±1.52 | 4.32±1.29 | |||||||||||
| Qiao, 2010 | 66±3 | 9±3 | (35) | ||||||||||||
| III | T: 30 | 49–72 | 6–21 | T: 40 mg i.v.drip. Qd-a,y | 1 month | 4.93±0.81 | 4.29±0.50 | 1.73±0.71 | 1.40±0.40 | N | N | N | N | ||
| C: 30 | 50–78 | 5–23 | C: -a,y | 4.80±0.29 | 4.78±0.80 | 1.75±0.18 | 1.73±0.60 | ||||||||
| Yuan, 2005 | III | T: 24 | N | N | T: 40 mg i.v. drip. Qd-b,x | 30 days | 8.17±1.04 | 6.49±1.30 | 2.89±0.33 | 1.75±0.15 | 1.25±0.13 | 4.95±0.09 | 3.96±0.08 | 3.28±0.02 | (47) |
| C: 24 | C: -b,x | 8.19±1.00 | 7.81±1.23 | 2.90±0.29 | 2.69±0.20 | 1.24±0.15 | 2.00±0.07 | 3.97±0.08 | 3.88±0.05 | ||||||
n, patient number enrolled; DN, diabetic nephropathy; T, breviscapine treatment group; C, control group; DM, diabetes mellitus; y, year; m, month; N, not mentioned; a, ACEI and/or ARB used; b, ACEI or ARB not mentioned; u, ACEI or ARB not used; w, antihyperlipidemics used; x, antihyperlipidemics not mentioned; z, antihyperlipidemics not used; HDL, high density lipoproteins; Fg, fibrinogen; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; Qd, once per day; i.v., intravenous.